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Ectopic expression of inactive forms of yeast DNA topoisomerase II confers
resistance to the anti-tumour drug, etoposide
YS Vassetzky*, G-C Alghisi, E Roberts and SM Gasser
Swiss Institute for Experimental Cancer Research (ISREC), Ch. des Boveresses 155, CH-1066 Epalinges/Lausanne, Switzerland.
Summary Drug resistance to anti-tumour agents often coincides with mutations in the gene encoding DNA
topoisomerase IIa. To examine how inactive forms of topoisomerase II can influence resistance to the
chemotherapeutic agent VP-16 (etoposide) in the presence of a wild-type allele, we have expressed point
mutations and carboxy-terminal truncations of yeast topoisomerase II from a plasmid in budding yeast.
Truncations that terminate the coding region of topoisomerase II at amino acid (aa) 750, aa 951 and aa 1044
are localised to both the cytosol and the nucleus and fail to complement a temperature-sensitive top2-1 allele at
non-permissive temperature. In contrast, the plasmid-borne wild-type TOP2 allele and a truncation at aa 1236
are nuclear localised and complement the top2-1 mutation. At low levels of expression, truncated forms of
topoisomerase II render yeast resistant to levels of etoposide 2- to 3-fold above that tolerated by cells
expressing the full-length enzyme. Maximal resistance is conferred by the full-length enzyme carrying a mutated
active site (Y783F) or a truncation at aa 1044. The level of phosphorylation of topoisomerase II was previously
shown to correlate with drug resistance in cultured cells, hence we tested mutants in the major casein kinase II
acceptor sites in the C-terminal domain of yeast topoisomerase II for changes in drug sensitivity. Neither
ectopic expression of the C-terminal domain alone nor phosphoacceptor site mutants significantly alter the host
cell's sensitivity to etoposide.
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DNA topoisomerase II is an essential nuclear enzyme that
relaxes supercoiled DNA in an ATP-dependent manner by
transiently introducing double-stranded breaks (for reviews
see Wang, 1985; Watt and Hickson, 1994). Several of the
most effective drugs used to treat small-cell lung cancer and
leukaemia cause topoisomerase 11-mediated DNA damage
and subsequent cell death (Liu, 1989). Repetitive treatment
with these chemotherapeutic agents often leads to multidrug
resistance (MDR) in the targeted cells and failure of the
chemotherapy. MDR can be acquired either through an
increase in the level of P-glycoprotein, a plasma membrane
efflux pump (reviewed in Endicott and Ling, 1989), or
through alterations in DNA topoisomerase II levels, its
primary structure and/or its phosphorylation state (reviewed
in Beck et al., 1993; Pommier, 1993; Corbett and Osheroff,
1993; Vassetzky et al., 1995). In many drug-resistant
mammalian cell lines, alterations in both P-glycoprotein
and DNA topoisomerase II are found (e.g. Granzen et al.,
1992), making it difficult to characterise and counteract drug
resistance.
DNA topoisomerases are the targets of a large variety of
commonly used anti-cancer drugs, which generally fall into
two classes: those that intercalate DNA, such as amsacrines,
and those that do not, such as epipodophyllotoxins (Liu,
1989). Although the literature on DNA topoisomerase II
inhibition is extensive, in most cases it is still unclear how the
drugs interact with topoisomerase II. Recently, a large
number of DNA topoisomerase II mutations conferring
drug resistance have been identified in cells of different
origins, including yeast (Jannatipour et al., 1993; Wasserman
et al., 1993; Wasserman and Wang, 1994a, b), cultured
mammalian cells and primary explants of tumours (Bugg et
al., 1991; Chan et al., 1993; Hinds et al., 1991; Lee et al.,
1992; Campain et al., 1994; Feldhoff et al., 1994) that
spontaneously developed drug resistance. The mutations
within the topoisomerase II gene that confer drug resistance
can be classified into three groups: (1) mutations clustered
between aa 449 and aa 493, which appear to affect the ATP-
binding domain; (2) mutations close to the active site (located
at aa 783 in yeast, aa 804 in human); and (3) mutations that
modulate the phosphorylation of the C-terminal domain of
topoisomerase II or which truncate the enzyme (Wasserman
and Wang, 1994a, b; McPherson et al., 1993; Takano et al.,
1991). The first two groups are characterised by a reduced
DNA cleavage activity (e.g. Lee et al., 1992; Liu et al., 1991),
which may explain the resistance phenotype, since less DNA
damage might be provoked by less active enzymes. The third
group is more enigmatic, since it was shown that the C-
terminal 220 aa of DNA topoisomerase II is not essential for
the enzymatic activity of the enzyme in Schizosaccharomyces
pombe (Shiozaki and Yanagida, 1991), Drosophila melanoga-
ster or Saccharomyces cerevisiae (Caron et al., 1994;
Crenshaw and Hsieh, 1993a,b), although it contains major
regulatory phosphoacceptor sites. Indeed, phosphorylation
has been demonstrated to modulate the enzymatic activity of
topoisomerase II in several species (reviewed in Cardenas and
Gasser, 1993). Recovery of a C-terminal truncation in a
screen for drug resistance suggested that this domain either
influences the interaction of anti-tumour drugs with
topoisomerase II or at least modulates their effect
(McPherson et al., 1993).
Yeast has been demonstrated to be a useful system for the
study of topoisomerase 11-mediated drug resistance (Nitiss
and Wang, 1988). However, in all reported cases resistance
has been screened under conditions in which the altered form
of topoisomerase II also provides the essential DNA
topoisomerase II activity for cell division. This automatically
restricts the mutants recovered to active forms of the enzyme.
With the long-term aim of understanding the mechanism of
inhibition and mapping sites of interaction, we have chosen
to characterise mutant forms of yeast topoisomerase II in a
system in which the ectopic expression of these mutants
confers a dominant resistance phenotype against the lethal
effects of etoposide (VP-16), in the presence of an expressed
wild-type TOP2 allele. This approach is highly relevant to the
situation in diploid human cells, where there are two copies
of the gene encoding topoisomerase IIla, and drug resistance
can initially reflect a dominant mutation in one allele. With
this approach we have screened C-terminal truncations of the
enzyme, an enzyme with a mutated active site, with mutated
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phosphoacceptor sites and have expressed the C-terminus
alone to identify forms of DNA topoisomerase II that shield
the yeast cell from the growth inhibitory action of VP-16.
Interestingly, resistance to an elevated level of VP-16
correlates with the expression of proteins that are inactive
and unable to complement a conditional top2 mutant.
Materials and methods
Drugs
VP-16 (etoposide) and VM-26 (teniposide) were obtained
from the drug synthesis branch of Bristol-Myers Squibb.
Both drugs were dissolved at a concentration of 20 mg ml-'
in dimethyl sulphoxide (DMSO). Each drug was diluted into
DMSO before spreading on solid yeast media, such that
varying amounts of drugs, but always equal volumes of
DMSO (1% final), were added to each plate.
Yeast strains
Yeast strains GA24 (MATa ura3 Gal' his3 barl suc2A9 pep4-
3), GA34 (formerly RS191 from R Sternglanz; MATa, ade2
ura3-1 his3-11 trpl-J leu2-3, 2-112 top2-1 ts), GA81 (formerly
DY36 from T Hsieh; MAT x/a ura3/ura3 trpl-J/trpl-J his3-
11,15/his3-11,15 leu2-3,112/lu2-3,112 adel/ADEJ lys2/LYS2
arg4-17/ARG4 TOP2/top2::LEU2 cir +), GAl 11 (formerly
362a from J Nitiss; MATa adel ura3 leu2 ISE2 tyro, and
GA199 (formerly DY25 from T Hsieh; MAT a/a ura3/ura3
trpl-J/trpl-J his3-11,15/his3-11,15 leu2-3,112/leu2-3,112 adell
ADEI lys2/LYS2 arg4-17/ARG4-17 cir+) were used in the
present work. Media were prepared as described in Rose et al.
(1990). Rich media [1% yeast extract, 2% glucose, 2%
bactopeptone (Difco), 50 mg 1` adenine] is termed YPD;
synthetic medium [0.67% yeast nitrogen base (Difco), 2%
glucose, with added amino acids, adenine and uracil, where
necessary] is called SD. Synthetic raffinose medium contains
2% raffinose and synthetic galactose medium contains 2%
galactose, both instead of glucose. When cells were cultured in
liquid medium, precultures were grown in 1% lactate/2%
glycerol before adding 2% galactose, to avoid glucose
inhibition of the GAL] UAS.
Plasmids
Yeast topoisomerase II C-terminal truncations were con-
structed as follows: pGalTop2A750 was constructed by
deletion of the 2.5 kb NheI-NheI fragment from the
pGalTop2 plasmid (Worland and Wang, 1989);
pGalTop2A951 was constructed from pGalTop2 by insertion
of a stop codon at aa 951; pGalTop2A 1044 was constructed by
deletion ofthe 1.4 kb AvrII- NheI fragment from the pGalTop2
plasmid; pGalTop2A 1236 was constructed from pGalTop2 by
insertion of a stop codon at aa 1236 (see Figure 2).
PGalTop2Y783F plasmid was a kind gift of Dr UK Laemmli
and contains a replacement of the active site tyrosine with
phenylalanine. The purified mutant protein is completely
inactive and cannot complement a top2 mutant (data not
shown). The construct expressing the C-terminus of the enzyme
was constructed by digestion of the pGalTop2 with AgeI and
PflMI and blunt end ligation of the filled-in AgeI end with the
trimmed PflMI end. It contains the first 4 aa of yeast
topoisomerase II and its C-terminal domain from aa 1068 to
aa 1429.
Viability assays
Viability of yeast strains harbouring various plasmids was
tested by plating 10 y1 of appropriate medium containing
either 400 or 103 yeast cells onto agar plates of different
growth media containing varying amounts of VP-16 drug
dissolved in DMSO as indicated. In most cases 4-fold serial
dilutions of the cells starting at 400 cells per 10 ,ul were plated
for each concentration of VP-16. The control plates
contained DMSO only. The agar plates were generally
incubated at 30°C for 3 days.
Temperature-sensitive top2 complementation assay
Yeast top2 truncation mutants as well as the control plasmid
(Yep24) and a plasmid pGalTop2 bearing a full-length TOP2
gene were transformed into GA34, which carries a top2-1's
mutation (Dinardo et al., 1984). Transformants were grown
in SD media lacking uracil and then were streaked onto
selective medium containing either glucose, raffinose or
galactose. Growth was monitored at 25°C, 30°C or 36°C,
as specified for 2-3 days.
Immunofluorescence
Immunofluorescence of paraformaldehyde-fixed yeast sphero-
plasts was carried out as described elsewhere (Klein et al.,
1992; Palladino et al., 1993), except that affinity-purified
rabbit antibodies raised against full-length yeast topoisome-
rase II were used. Slides were mounted with 50% glycerol in
phosphate-buffered saline (PBS) and 2 jug ml-' DAPI (4'6-
diamidino-2-phenylindol-dihydrochloride) and photographed
on a Zeiss Axiophot microscope using a lOOx Pan Neofluar
objective.
Protein extracts and Western blots
Total protein extracts were obtained from the pep4-3 mutant
strain GA24 transformed with the plasmids carrying either
the wild-type or mutant forms of TOP2 downstream of the
GALI UAS. Cultures were grown in glucose medium before
being transferred to glycerol/lactate. Induction was for 2 h in
the presence of 2% galactose and samples were taken from
all three growth conditions. Cells were washed and frozen in
liquid nitrogen before being lysed by vortexing with glass
beads in a buffer containing 50 mM Tris-HCl pH 7.7, and
protease and phosphatase inhibitors (Cardenas et al., 1992).
Aliquots were run on SDS-PAGE to determine relative
protein concentrations and equal amounts of total protein
from each condition were analysed by immunoblotting with
affinity-purified antibodies directed against epitopes in the N-
terminus of topoisomerase II. The peroxidase-coupled
secondary antibody signal was visualised by enhanced
chemiluminescence (ECL, Amersham).
Growth curves
Growth curves were measured by dilution of overnight
cultures to 5 x 105 cells ml-' in SD-uracil and manual
counting of cells at hourly intervals in duplicate. Doubling
time was calculated in the most rapid phase of growth,
usually between 3 and 12 h after dilution into fresh medium.
Results
The budding yeast, S. cerevisiae, has been used extensively
as a test system for mutations that confer resistance to anti-
tumour drugs that target topoisomerase II, but generally in
screens for recessive mutations that leave the topoisomerase
II active, but drug-resistant (Jannatipour et al., 1993;
Wasserman and Wang, 1994a,b; Liu and D'Arpa, 1992;
Nitiss et al., 1992). We have chosen to screen for forms of
topoisomerase II that confer a dominant resistance
phenotype like that reported in transfected human cells
(Gudkov et al., 1993), to eliminate the restriction that the
drug-resistant form of topoisomerase II be enzymatically
active.
Sensitivity of yeast to VP-16 depends on the culture media
To optimise the yeast system for this analysis we have
screened different yeast strains under different media
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Figure 1 Effect of culture medium on drug resistance. Four yeast
strains (GA24, GA81, GAl11 and GA199; see Materials and
methods) were grown overnight to a density of 107 cells ml -',
and were diluted to 4 x 104 cells ml-' in the culture medium.
Four hundred cells (10 Ml) from each strain were plated onto a
series of plates containing increasing concentrations of VP- 16 (0,
2, 6, 20, 50 and 100 jg ml-l) on a rich (YPD, a) or complete
synthetic medium (SD, b). For c, two strains, GA24 and GA81
were transformed either with the Yep24 vector (multi-copy URA3
plasmid) or with the same plasmid carrying the GALI-TOP2
construct (here labelled pTOP2, Worland and Wang, 1989). Cells
were grown overnight in SD-uracil and 400 cells were plated on
selective medium (SD-uracil) containing a titration of the VP-16
drug (0, 1, 3, 10, 30 and 100 Mg ml-l). After 3 days at 30°C, the
plates were photographed. All plates contain 1% DMSO final
concentration.
conditions to assess their sensitivity to the anti-tumour drug,
VP-16. These strains include GA24 and GA199, haploid and
diploid strains respectively, that are wild-type for TOP2;
GA81, a diploid strain carrying one disrupted copy of TOP2;
and GAl11, a strain carrying the ISE2 mutation that was
reported to enhance permeability to m-AMSA (Nitiss and
Wang, 1988). Standardised plating assays show only slight
variation among strains in their sensitivity to VP-16, with the
ISE2 strain showing no more sensitivity than the other
strains tested. We find, however, that all strains are more
sensitive to VP-16 on synthetic (SD), as compared with rich
(YPD) medium (Figure la for rich media, and lb for SD or
synthetic media). This may reflect media-dependent altera-
tions in plasma membrane permeability or changes in drug
metabolism within the cell. The plating of cells in osmotically
stabilised media (with IM sorbitol) after enzymatic removal
of the cell wall, did not alter the lack of drug sensitivity on
YPD, thus the cell wall does not limit drug accessibility (data
not shown).
Our system for ectopic expression of topoisomerase II in
yeast requires growth under selective conditions (SD lacking
uracil). If our test strain, GA24, carries only the vector
(Yep24), cells are sensitive to as little as 30 jMg ml-' VP-16,
and no growth is observed at either 50 ,ug ml -' (not shown)
or 100 jug ml-' (Figure lc). When the Yep24 vector carries
the full length TOP2 gene, we see growth inhibition at
10 jMg ml-' VP-16 instead of 30 or 100 jug ml-' (Figure lc).
The plasmid-borne TOP2 gene is expressed at a low level
under these conditions, but nonetheless renders the cell
slightly more sensitive to the inhibitor. This is consistent
with previous papers reporting that increased levels of
topoisomerase II correlate with the cell's sensitivity to VP-
16, VM-26 and other topoisomerase II targeting reagents
(Nitiss et al., 1992; Eder et al., 1993; and reviewed in Beck
et al., 1993; Corbett and Osheroff, 1993; Liu and D'Arpa,
1992; Alton and Harris, 1993). In the case of GA81, which
is a diploid heterozygotic for the TOP2 locus, we observe
somewhat better growth in the presence of VP-16, perhaps
reflecting an overall lower level of enzyme. For the sake of
standardisation, most experiments will be presented using
GA24, although similar results were also obtained with
GA81.
Characterisation of topoisomerase II mutants expressed in
vivo, and their effect on viability
The above results show that yeast carrying either a vector
alone or the vector with the TOP2 gene are sensitive to VP-
16 at concentrations between 10 to 30 tg ml-'. In order to
analyse the effect of mutant forms of topoisomerase II on
drug sensitivity, we checked whether strains expressing the
plasmid-borne forms of topoisomerase II were viable in the
absence of drugs, whether the truncated forms complement a
temperature-sensitive top2 mutation, and, if so, at which
levels of expression. The constructs used are C-terminal
truncations, of which all but the shortest leave the active site
of the enzyme intact and retain the conserved regions
homologous to type II topoisomerases, including GyrA and
GyrB of E. coli (see Figure 2). The truncations remove the
major sites of casein kinase II modification in the C-terminal
200 aa of the enzyme (indicated as arrows above the gene),
and in all but the truncation at aa 1236, nuclear localisation
signals (between aa 1166 and 1208, Caron et al., 1994) are
removed. All constructs are inserted in the same multicopy
vector with a galactose-inducible promoter, which allows
differential levels of transcription depending on the carbon
source, i.e. glucose allows low levels; raffinose or glycerol/
lactate, intermediate; and galactose, high levels of expression.
Although the GALI UAS is repressed on glucose, sufficient
topoisomerase II is synthesised to allow growth in a top2-1
temperature-sensitive mutant at non-permissive temperature
(see Table I, 36°C). We similarly screened for the ability of the
truncated forms to complement the top2-1 temperature-
sensitive mutant at non-permissive temperature (36°C) on
different carbon sources. None of the shorter truncations
(pGalTop2AI044, A951 or A750) is able to maintain mitotic
growth at any level of expression (Table I), suggesting that
these are inactive forms of the enzyme. The truncation at aa
1236 (A1236) complements better on raffinose than on glucose,
suggesting that its level of expression must be elevated to
provide sufficient topoisomerase II activity for mitotic growth
(Table I). Galactose-induced expression of either the full-
length TOP2 or the A1236 gene from the multicopy vector is
lethal both for wild-type yeast cells (data not shown) and for
the top2-1 ts mutant at permissive temperature (see Table I,
see galactose, 25°C and 30°C). In contrast, none of the shorter
C-terminally truncated forms of topoisomerase II is detri-
mental to growth at any level of expression (see Table I).
The inability of the shorter topoisomerase II proteins to
inhibit growth when overexpressed, or to complement top2-1
at low levels of expression could simply reflect instability of
the message or protein. To check this we have probed for the
presence of the truncated gene products, as well as the wild-
type protein and an active site mutant (Y783F) in whole cell
extracts of GA24 transformed with the appropriate plasmids
and grown in galactose. By Western blotting equal amounts of
whole cell extract from each indicated transformant, we
readily detect all the mutated forms of topoisomerase II
(Figure 3c). For comparison of these protein amounts with
endogenous levels of full-length enzyme, a longer exposure of
the blot of galactose grown cells is shown (Figure 3d). In all
cases the correct-sized proteins are present, and on galactose
all are expressed and stable at levels much greater than the
endogenous protein. The truncations are below the level of
detection under standard blotting conditions in cells grown on
either glycerol/lactate or on glucose media (Figure 3a and b).
In conclusion, the full-length TOP2 construct and the
truncation at A1236 can complement a top2-1Js mutant on the
multicopy vector in glucose-containing media, and at this
level of expression no construct is detrimental to growth. The
truncations at A1044, A951 and A750 cannot complement a
top2-1's mutant, although the proteins are synthesised and are
relatively stable. Since our system does not require that the
plasmid-borne topoisomerase II complement a top2 mutant,
we could screen for drug resistance conferred by the plasmid-
borne constructs on glucose, and thus avoid any toxicity
owing to high level expression of the polypeptides.
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Figure 2 Construction of the C-terminal truncations of the yeast TOP2 gene. The truncations were constructed as follows: A750
was constructed by deletion of the 2.5 kb NheI-NheI fragment from the pGalTop2 plasmid (Worland and Wang, 1989). The last
amino acid before the stop that is native to yeast topoisomerase II is aa 750, hence its name. A951 was constructed from the
pGalTop2 by insertion of a stop codon at aa 951. A1044 was constructed by deletion of the 1.4 kb AvrII-NheI fragment from the
pGalTop2 plasmid; the last amino acid native to yeast topoisomerase II is aa 1044. A1236 was constructed from pGalTop2 by
insertion of a stop codon at aa 1236. All truncations were constructed in the host plasmid pGalTop2 (Worland and Wang, 1989).
The arrows above the full-length topoisomerase II map indicate putative sites of casein kinase II phosphorylation, whereas NLS
indicates the proposed location of the nuclear localisation signal (Shiozaki and Yanagida, 1991; Caron et al., 1994; Crenshaw and
Hsieh, 1993a, b). Alignment with the prokaryotic type II topoisomerase (gyrase) is indicated below the yeast enzyme.
Table I A screen for viability of the top2-l's strain carrying the various TOP2 alleles on the multi-copy plasmid pGalTop2 (see Figure 2) at
permissive (25°C), semi-permissive (30°C) and non-permissive temperatures (36°C)
Glucose Raffinose Galactose
Construct 250 300 360 250 300 360 250 300 360
Yep24-no topoll + + - + + - + + -
YepGalTop2 A750 + + - + + - + +
YepGalTop2 A951 + + - + + - + + -
YepGalTop2 A1044 + + - + + - + + -
YepGalTop2 A1236 + +/- -1+ + + + +/
YepGalTop2 + + + + + + - - -
All transformants were grown on synthetic medium lacking uracil, but the carbon source (indicated above the growth temperature) was varied to
modulate expression levels. The mutant genes are under control of a GALI UAS, and expression levels are highest on galactose, intermediate on
raffinose and low on glucose. Normal growth is indicated by +, no growth by -, and slow growth by + /- or / +.
Truncated forms of topoisomerase II can confer a dominant
drug resistance phenotype
We have plated serial dilutions of GA24 cells transformed with
either the truncated or wild-type TOP2 alleles in the pGalTop2
vector onto media containing increasing amounts of VP-16.
Transformants of GA24 (Figure 4) carrying wild-type TOP2
grow poorly, or not at all, on plates containing 20 jug ml-I VP-
16. Resistance to up to 40 pg ml-' VP-16 is conferred by the
presence of truncated constructs pGalTop2A951,
pGalTop2Al044 and pGalTop2A1236, while strains carrying
pGalTop2A750 resemble those carrying the wild-type gene
(Figure 4). In the diploid GA81, resistance of the same
constructs was observed at 80 jg ml-' VP-16 (Figure 5).
Finally, a very similar pattern of slightly elevated resistance was
observed when etoposide was replaced by the related
topoisomerase II-inhibitor, teniposide (VM-26, data not
shown), consistent with the idea that these two agents interact
with the enzyme in a similar manner. In all cases the resistance
to elevated drug levels is reproducible and construct-dependent.
To see if the C-terminus of topoisomerase II alone can
influence drug resistance, the first 4 aa of topoisomerase II
were fused to the last 361 aa, and the construct was introduced
into the two test strains GA24 and GA81. The C-terminus of
topoisomerase II is not highly stable, but can be detected by
Western blot (data not shown). The level of expression
attained has no effect on growth rate in the absence of drug,
nor does it confer drug resistance (data not shown). Assuming
that the larger fragments of topoisomerase II confer drug
resistance by binding the drug, but not damaging DNA, our
results suggest that the C-terminal domain of topoisomerase II
is not necessary for binding epipodophyllotoxins, nor are the
first 750 aa sufficient for efficient interaction.
The active site mutant Y783F confers a dominant drug
resistance phenotype when expressed ectopically
Two phenomena might account for the resistance to an
elevated level of topoisomerase II inhibitors conferred by the
A1044 construct, which lacks a dimerisation domain, the
nuclear localisation signal (NLS), and fails to complement
top2 deficiency in vivo. First, if the A1044 protein is primarily
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Figure 3 Detection of the truncated topoisomerase II proteins by Western blot. GA24 yeast cells were transformed with the
truncation mutants indicated in Figure 2, the Y783F active site mutant or the wild-type TOP2 gene, all carried on the pGalTop2
plasmid. Cells grown on different media at 30°C were lysed and whole-cell extracts were analysed by 7.5% SDS-PAGE. Equal
amounts of protein from each transformant were transferred to a nitrocellulose filter and probed with anti-topoisomerase II N-
terminal antibodies, which were visualised by enhanced chemiluminescence (ECL, Amersham). (a) The indicated transformants were
grown in glucose medium. (b) The same strains were grown in glycerol/lactate medium. (c) Cells grown in glycerol/lactate medium
supplemented with 2% galactose for 2h before lysis. (d) A longer exposure of the gel shown in (c) so that the full-length
topoisomerase II can be seen (arrow). The spot in (a) indicates a proteolytic product that cross-reacts with the antibody. The smaller
bands seen upon galactose induction are consistent with the sizes for truncated forms of topoisomerase II expected from the
constructs. Molecular weight markers are given as kDa.
0 10 20 40 80 0IQ mi-1
Figure 4 Drug resistance of GA24 transformed with truncated forms of DNA topoisomerase II. The GA24 strain was transformed
with plasmids containing the full-length TOP2 gene (pGalTop2, labelled WT), different C-terminal truncations of yeast
topoisomerase II (sites of truncation indicated by A750, A951, A1044 and A1236). Equal numbers of cells in a dilution series (400,
100 and 25 cells always in 10 pl) were plated on minimal selective medium containing increasing concentrations of etoposide (VP-16,
as indicated). Growth was for 3 days at 30°C.
cytoplasmic, as expected from its lack of NLS, it may bind
the drug before it has access to the nuclear-localised, full-
length topoisomerase II. Alternatively, having an inactive
complement of enzyme may simply reduce the damage
induced by the drug by not forming the 'cleavable complex'
in which the enzyme is covalently bound to DNA. To see
whether catalytic inactivity is sufficient to confer drug
resistance, we tested the plasmid-borne active site mutant
(Y783F) in an identical assay.
As shown in Figure 6, low-level expression of the active
site mutant (pGalTop2Y783F) is sufficient to confer drug
resistance at concentrations up to 80 pg ml-1 etoposide. In
repeated assays the resistance conferred by the active site
mutant is reproducibly higher than that conferred by the
truncated forms of topoisomerase II (A1236 and A1044; ER
and YSV, data not shown). Slight variations observed in the
level of drug tolerated by the transformants are likely to
reflect varying plasmid and expression levels in different cells.
Mutation of CKII phosphorylation sites does not alter drug
sensitivity
We have previously identified casein kinase II as the major
kinase modifying yeast topoisomerase II in vivo, and have
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Figure 5 Drug resistance of GA81 transformed with truncated
forms of DNA topoisomerase II. Roughly 103 cells of the diploid
yeast strain GA81 transformed either with the truncation mutants
pGalTop2A750, pGalTop2A951, pGalTop2Al044 or
pGalTop2Al236 or with pGalTop2 carrying wild-type TOP2
(WT) or the Yep24 plasmid alone (control) were plated on
selective medium containing increasing amounts of VP-16 (0, 8,
25 and 80 jMg ml- 1) and grown for 3 days at 30°C.
mapped the sites of modification to the C-terminal domain
(Cardenas et al., 1992; Dang et al., 1994; Alghisi et al., 1994).
The putative acceptor sites are found clustered together on a
limited number of tryptic peptides, which allowed us to create
three groups of point mutations that eliminate the target sites
on three different peptides (see map, Figure 6; Cardenas et al.,
1992; Alghisi et al., 1994). The three series of clustered
mutations sites (replacement of Ser or Thr by Ala or Gly),
were at aa 1087 and aa 1088 (labelled 6); aa 1267, aa 1270 and
aa 1273, (labelled 8); and aa 1357, aa 1364, and aa 1366
(labelled 9). By substitution of acceptor sites, the mutations
mimic an under-phosphorylated form of topoisomerase. In
contrast to the active site mutant, these plasmids carrying
point mutations in the C-terminus of topoisomerase II do not
significantly alter the sensitivity of the host cell to VP-16
(Figure 6).
Are the resistance-conferring forms of topoisomerase II
cytosolic?
The active site mutant and the two truncations, A951 and
A1044, are non-complementing activities that confer drug
resistance. The longer truncated form of topoisomerase II
(A1236) is active, but unlike the hypersensitivity conferred by
expression of the full-length protein, expression of A1236
confers drug resistance. Is this because it is less efficiently
localised to the nucleus (e.g. Crenshaw and Hsieh, 1993b)? To
check the intracellular localisation of the mutant forms of
topoisomerase II, we have induced the topoisomerase II
constructs for a limited time on galactose and used indirect
immunofluorescence to reveal the distribution of the enzyme
in paraformaldehyde-fixed cells. Figure 7 shows the distribu-
tion of the mutant and wild-type TOP2 proteins, as detected
by indirect immunofluorescence. Because our antibodies
cannot distinguish between truncated and wild-type topoi-
somerase II forms, we always detect low-level immunofluor-
escence of the endogenous, exclusively nuclear wild-type
enzyme (see Figure 7a; Klein et al., 1992).
The deletion of the C-terminal 193 aa (A1236) leads to
the appearance of significant cytoplasmic staining in
addition to strong nuclear staining, while deletion of 385
aa (A1044) leads to a strong cytoplasmic staining with weak
nuclear staining (Figure 7c and d). Cytoplasmic staining is
also observed in the shorter truncations A951 and A750,
although in these cases the endogenous, wild-type topoi-
somerase II gives a more prominent signal, because the
truncated forms contain fewer epitopes recognised by the
polyclonal antibody. As expected, in the strain carrying the
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Figure 6 Drug resistance of GA24 transformed with the active
site mutant and casein kinase II target site mutants of DNA
topoisomerase II. The GA24 strain was transformed with
plasmids containing the wild-type full-length TOP2 gene
(labelled WT), the full-length TOP2 gene with a Y783F mutation
at the active site (labelled Y783F) or the full-length TOP2 gene
with the point mutations indicated above the linear map of yeast
TOP2, all of which mutate potential casein kinase II acceptor
sites from the phosphate acceptor residue to a non-charged non-
acceptor amino acid. The mutated sites are clustered in three
groups representing tryptic peptides numbered 6, 8 and 9; as
indicated in the map of topoisomerase II and defined in Cardenas
et al. (1992). Equal numbers of cells in serial dilutions (400, 100
and 25 cells) were plated on minimal selective medium (SD-uracil)
containing increasing concentrations of etoposide (,ug VP-16
ml-1, as indicated). Growth was for 3 days at 30°C.
pGalTop2Y783F active site mutant, we observe exclusively
nuclear staining. The negative control with only secondary
antibodies is shown in Figure 7g, confirming that the
cytosolic staining in Figure 7b -e is not due to the
secondary antibody. Similar results of protein distribution
were obtained in crude fractionations of the yeast cell into
cytoplasmic and nuclear fractions using sucrose gradients
(data not shown).
Ectopic expression of truncated forms of topoisomerase II do
not interfere with growth rates
The enhanced drug resistance observed in some transfor-
mants might be attributed to an altered cell cycle that could
either allow degradation of the drug or longer repair times
after damage is incurred. To check for alteration in the
growth pattern of the transformants, growth curves and
doubling times were calculated for the strains carrying
truncated forms of topoisomerase II. All have essentially
identical growth curves (Figure 8), with only the strain
carrying the A951 mutant showing a slightly longer doubling
time (156 min doubling time, as opposed to 139 min or 140
min for the wild-type or A1044 transformant respectively).
Thus, we see no consistent correlation between the division
time of these strains and their drug resistance, suggesting
again that the resistance phenotype probably results directly
from expression of the non-complementing topoisomerase II
domains.
Discussion
Drug resistance due to alterations in DNA topoisomerase II
levels or structure occurs frequently in situations of high-dose
chemotherapy (Beck et al., 1993; Corbett and Osheroff,
1993). It is essential to understand the mechanisms by which
cells become resistant to topoisomerase II inhibitors to be
able to counter this tendency and increase the chances of
successful anti-tumour treatment. Three kinds of experi-
mental systems are used to study the phenomenon of
topoisomerase II-related drug resistance. The first approach
is based on the isolation and characterisation of drug-
resistant cancer cells from patients or laboratory animals
(Long et al., 1991; Danks et al., 1993). The second consists of
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Figure 8 Growth curves of GA24 transformed with a multicopy
vector carrying mutant and wild-type TOP2 alleles. GA24 yeast
cells transformed with either the wild-type pGalTop2 plasmid, or
with the indicated truncation mutants on pGalTop2, were grown
overnight in a SD-uracil liquid medium to a density of c 2 x 107
cells ml- l then diluted to a density of 5 x 105 cells ml- 1 into fresh
medium and grown at 30°C. Samples were taken at the indicated
times, immediately fixed by addition of formaldehyde to a final
concentration of 3.7%, and counted manually in duplicate. The
data represent the results of two independent experiments.
f AY783F
Control
Figure 7 Analysis of subcellular localisation of the truncated
topoisomerase II. Immunofluorescence to topoisomerase II is
shown for GA24 yeast cells carrying the uninduced wild-type
TOP2 gene (WT, a, g) or transformed with the truncation
mutants as indicated in the pGALTOP2 vector (b-f). Transcrip-
tion was induced by the addition of galactose for 2h at 30°C (for
pGalTop2Al044, pGalTop2Al236 and pGalTop2Y783F; and
for 6h in the case of pGalTop2A750 and pGalTop2A951). Cells
were spheroplasted, fixed and probed with affinity-purified anti-
topoisomerase II and a FITC-conjugated secondary antibody.
DNA visualised by DAPI is shown on the left and the FITC
signals from the anti-topoisomerase II reaction on the same cells
to the right. The background staining contributed by the sec-
ondary antibody alone is shown in g. Bar=4 gm.
selection in vitro of cultured cancer cells resistant to
topoisomerase II-targeted drugs (McPherson et al., 1993;
Chan et al., 1993), and the third approach uses simple and
genetically accessible experimental systems like yeast to
analyse the phenomenon of drug resistance (Wasserman
and Wang, 1994a, b; Nitiss and Wang, 1988; Jannatipour et
al., 1993; Liu et al., 1994). To obtain drug-resistant strains of
yeast, several groups have mutagenised the gene for
topoisomerase II in vitro and assessed the effect of the
mutant gene on drug resistance in a temperature-sensitive
yeast strain (Wasserman and Wang, 1994a; Liu et al., 1994).
A variation of this approach involves the transfection by a
retroviral vector containing an expression library of
topoisomerase Ilox subfragments in human cultured cells
and the subsequent selection of stable drug-resistant
transformants (Gudkov et al., 1993). These workers found
that the majority of the resistance-conferring clones encoded
antisense RNA that lowered cellular levels of topoisomerase
Ila. However, three sense clones apparently allowed the
synthesis of fragments of the enzyme which were able to
enhance resistance to VP-16 and/or m-AMSA by 3- to 5-fold.
No immunolocalisation or Western blotting was done to
confirm this interpretation, but if correct, it might provide a
means to screen for minimal drug binding sites within
topoisomerase II.
We have adapted this novel approach and applied it to the
study of drug resistance in yeast, by screening for a drug
resistance phenotype mediated in trans by plasmid-borne
forms of topoisomerase II in strains that contain a wild-type
DNA topoisomerase II enzyme. Our system thus reflects the
situation in mammalian cells, where mutations incurred in
one of the two alleles confer a dominant drug resistance
phenotype, while the wild-type allele provides the essential
enzymatic activity.
We find that the low level expression of truncated forms of
yeast topoisomerase II leads to increased survival in the
presence of VP-16 and VM-26, while ectopic expression of
the wild-type allele confers enhanced sensitivity to these anti-
tumour drugs. The most efficient drug resistance is mediated
by forms of topoisomerase II that are unable to complement
a top2-1's mutant. A smaller truncation that removes the
active site (A750) confers little or no resistance, suggesting
that the N-terminal 750 aa are not sufficient for this
phenotype. Importantly, two truncations that confer drug
resistance (A1044, A951) are not detrimental to the growth
rate of cells and cannot complement a lethal top2 mutation,
even when overexpressed. We demonstrate that these forms
are stable and are largely localised to the cytoplasm (Figure
6), suggesting that they may act as a cytosolic sink for the
drug, diminishing the level of etoposide that reaches the
nuclear topoisomerase II. An alternative explanation is that
the mutant forms have an allosteric effect on the wild-type
topoisomerase II, which could reduce either the enzyme's
accessibility or the effects of VP-16 binding. However, one
would expect such allosteric effects to interfere with
topoisomerase II function and cause a growth defect,
particularly when the truncated form is overexpressed. This
was not observed (Table I; Figure 8).
A second pattern of drug resistance is mediated by the
active site mutation (Y783F). The Y783F mutant form of
DAPI (Y-Topo 11
WT
A750
a
b
c
d
e
A951
A1044
Al 236
. 8
.-E
Dominant etoposide resistance in yeast
YS Vassetzky et al
1208
topoisomerase II is catalytically inactive and non-comple-
menting (G-C Alghisi, unpublished results), but in contrast to
A1044, it is entirely nuclear localised. The high level of drug
resistance may either reflect preferential interaction of the
drug with the mutated enzyme that can no longer damage the
genomic DNA, or the presence of heterodimers (formed from
one wild-type and one mutant subunit) that effectively
reduces the active population of topoisomerase II. Drug
resistance in this latter case would be similar to many
instances observed in drug-resistant mammalian cell lines
with lowered levels of active topoisomerase II (reviewed in
Beck et al., 1993). Further study of differentially tagged
forms and purification of enzyme may be required to fully
explain the mechanism of the drug-resistance conferred by
expression of an inactive form of topoisomerase II in yeast.
Two previous reports also found truncated forms of
topoisomerase II that confer dominant drug resistance,
although the presence of secondary point mutations was
not excluded. In one case a murine topoisomerase IIoc,
truncated at aa 1148, confers resistance to adriamycin in the
presence of the wild-type topoisomerase II allele (McPherson
et al., 1993), as does an unidentified truncation that produces
a 160 kDa form of topoisomerase II with altered subcellular
localisation (Feldhoff et al., 1994). In yeast two truncated
forms, terminating at aa 1235 and aa 1191, respectively, were
shown to confer a low level of drug resistance to amsacrine
(at 10 ,g ml-'; Wasserman and Wang, 1994a). In contrast to
our conditions, these mutant forms were selected for their
ability to support growth as well as confer drug resistance,
hence they were at least partially nuclear and enzymatically
active (Wasserman and Wang, 1994a; Caron et al., 1994).
Our screen for dominant drug resistance in yeast can be
readily applied to domains of the human topoisomerase Ilx
gene, since we are not dependent on complementation of the
top2's deficiency.
A final class of mutation that correlates with drug
resistance involves the phosphorylation level of topoisome-
rase II. It is known that phosphorylation of topoisomerase
II increases its activity in vitro, while dephosphorylation
lowers enzymatic activity (reviewed in Cardenas and Gasser,
1993). Consistently, an amsacrine-resistant cell line was
reported to have a 2- to 3-fold drop in the population of
newly synthesised, phosphorylated topoisomerase IIlc
(Ganapathi et al., 1993). On the other hand, a hyperphos-
phorylated form of topoisomerase II was also reported in an
etoposide-resistant human cancer cell line (Takano et al.,
1991). Interestingly, in this case hyperphosphorylation
coincided with a 10-fold decrease in the topoisomerase II
protein level, which effectively lowered the concentration of
drug target. Osheroff and colleagues have demonstrated that
phosphorylation by either CKII or PKC in vitro renders
topoisomerase II less sensitive to inhibition by VP-16 or
VM-26 (DeVore et al., 1992), thus suggesting that a
hyperphosphorylated form of topoisomerase II might
correlate with drug resistance in vivo, while cells bearing
an under-phosphorylated form might be less resistant. We
have tested point mutations that significantly reduce the
number of CKII target sites on topoisomerase II (Alghisi et
al., 1994), and find no significant variation in drug
resistance. This lack of increased sensitivity (or enhanced
resistance) suggests that the previously reported correlation
between drug resistance and the phosphorylation state of
topoisomerase II is either invalid for yeast, reflects
phosphorylation by another kinase, or is due to other
parameters, such as lowered expression levels of the enzyme
(Takano et al., 1991; Ganapathi et al., 1993). We also
observe that elimination of the C-terminal domain, which
contains targets for other kinases as well as CKII, improves,
rather than reduces, drug resistance in yeast.
The level of drug resistance we observe in yeast is only 2-
to 4-fold over the sensitivity of a wild-type strain. This
appears modest when compared to the drug resistance in
tumour cell lines, which can grow in 20- to 50-fold the
amount of drug tolerated by normal cells (reviewed in Beck
et al., 1993). Drug-resistant tumour cells usually incur
multiple mutations, however, and the resistance is an
accumulative effect of mutations in MDR], topoisomerase
IIc and perhaps other unknown targets of mutation. Our
degree of enhanced resistance is comparable to the levels
observed in transfected HeLa cells, in which small
subfragments of human Top20t gene were randomly
expressed (Gudkov et al., 1993). In this HeLa cell study, it
was not determined whether the cloned fragment made a
stable polypeptide product, nor was the subcellular
localisation of the products examined. Indeed, the predicted
polypeptide products were small enough to readily diffuse
through nuclear pores (< 20 kDa), hence the observed effect
might have been due to an allosteric down-regulation of the
endogenous topoisomerase II activity. Possible alterations in
the growth rates of the drug-resistant cells were not
reported.
Our study here has clearly established the fact that a low-
level expression of inactive forms of DNA topoisomerase II
can confer a certain level of drug resistance on otherwise
wild-type yeast cells, i.e. cells with a wild-type genomic allele
of TOP2. This is clinically relevant, since at early stages in
the development of drug resistance, a single mutation in one
of the alleles encoding topoisomerase IIo may initially confer
a growth advantage on a subset of tumour cells. These cells
are then likely to incur further mutations that confer yet
higher levels of drug resistance. One immediate application
of this assay for a plasmid-mediated drug resistance will be
to define protein domains that bind topoisomerase II-
inhibiting drugs with high efficiency. Understanding both
the mode and site of action for topoisomerase II-targeted
drugs will be essential for the improvement of high-dose
chemotherapy.
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